Physician profile
Shirley Shiller
NPI 1710195235
$1,340,322.97
in general payments reported to CMS, 2019-2025
30 companies · $256K in 2025
The $256K reported for 2025 was more than what 99% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215K · 2020: $115K · 2021: $141K · 2022: $193K · 2023: $184K · 2024: $238K · 2025: $256K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $425K · Consulting Fee: $152K · Travel and Lodging: $92K · Food and Beverage: $8,219 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $424,935.37 |
| Consulting Fee | $152,024.63 |
| Travel and Lodging | $91,824.53 |
| Food and Beverage | $8,219.04 |
| Education | $286.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $638,347.40 | 2019-2025 | Lynparza, Tagrisso, Enhertu |
| Lilly USA, LLC | $211,076.78 | 2021-2025 | Retevmo |
| Astellas Pharma US INC | $97,192.08 | 2022-2025 | Vyloy |
| Astrazeneca Uk Limited | $80,693.58 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| Genentech USA, INC. | $55,184.58 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $31,521.13 | 2019-2024 | Keytruda |
| Roche Diagnostics Corporation | $29,482.16 | 2021-2025 | Benchmark Special Stains Wash II |
| Bayer Healthcare Pharmaceuticals INC. | $28,720.51 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25,015.77 | 2021-2023 | Exkivity |
| E.R. Squibb & Sons, L.L.C. | $23,043.52 | 2019-2025 | |
| Pfizer INC. | $15,212.19 | 2024-2025 | |
| Mirati Therapeutics, INC. | $14,849.47 | 2023-2025 | Krazati |
| Eli Lilly and Company | $14,700.63 | 2019-2024 | |
| Abbvie INC. | $13,210.10 | 2023-2025 | |
| Roche Molecular Systems, INC. | $11,609.79 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $9,327.43 | 2019-2025 | Vectibix |
| Array Biopharma INC | $7,475.00 | 2021-2023 | Braftovi |
| Novartis Pharmaceuticals Corporation | $4,892.50 | 2020-2025 | |
| Partner Therapeutics, INC. | $4,575.00 | 2025 | Bizengri |
| Promega Corporation | $4,400.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $4,050.30 | 2025 | |
| Ventana Medical Systems, INC. | $3,961.49 | 2024 | |
| Daiichi Sankyo INC. | $3,605.00 | 2023-2025 | Enhertu |
| Genzyme Corporation | $2,017.22 | 2023 | |
| Alexion Pharmaceuticals, INC. | $1,860.00 | 2024 | |
| Blueprint Medicines Corporation | $1,770.51 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $1,374.00 | 2023 | Libtayo |
| Incyte Corporation | $1,014.88 | 2019-2020 | |
| Caris Mpi, INC. | $100.00 | 2025 | Mi Cancer Seek |
| Genentech, INC. | $39.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirley Shiller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.